Conference Service Mandl

abstract: Workshop Topics: Virtual Screening & Docking; Structure-based Drug Design; Ligand Optimisation & Library Design; Structure Search, Similarity and Property Estimation; Data Mining, Analysis & Visualisation; Pharmacophore Modelling for Lead Identification; Fragment-based Drug Design; QSAR-based Predictive Toxicology; Quantitative Spectrometric Data-Activity Relationship Modelling.

abstract: IQPC’s Pharma IQ’s Biobanking conference will show professionals working in Labs, Biorepositories, Bioanalysis and R&D how to set up productive biological sample management efforts; including assessing the latest automation systems; how to accurately assess samples including DNA, Blood and Human tissues; understand and work with Regulations and Bioethical challenges; and effectively collect and manage patient information.

abstract: This conference will encompass six sessions in two days. Each will focus on a different area of Drug Discovery from selecting compounds for the corporate collection, liquid handling and detection technologies, plus advances in assay development and screening. Two sessions will address the biochemistry of two important different target classes: Enzymes and G-protein coupled receptors. Biopharmaceuticals will form the sixth session. As with our highly successful meeting in 2007, attendees will hear world class speakers discussing the challenges facing the drug discovery scientist. The scientific sessions will be complemented by plenary keynote presentations from two of the field's foremost researchers, a poster session and a vendor exhibition with over 80 exhibitors.

abstract: A brand new DIA Conference featuring an expert programme committee and speakers from the EMEA, CHMP Working Group, EFPIA, European Commission, EBE, EuropaBio, Eucomed and senior representatives from industry. The conference will involve all stakeholders including regulators, industry, academia and patient groups. The conference is organised over two days. The first day will address the progress with the implementation of the Innovative Medicines Initiative and the EMEA initiatives in relation to support innovation including the qualification of biomarkers and new methodologies. The second day will focus on the practical aspects to implement the Regulation on Advanced Therapy.

abstract: The Quality Control Laboratory, in both the R & D and Operations environment, is a key element of the supply chain and has a particularly significant impact on lead times, affecting speed of drug development and overall site manufacturing performance.

As the UK pharmaceutical industry faces ever-increasing competition from abroad, the enhancement of laboratory productivity to improve the product-process development cycle and manufacturing efficiency has become even more crucial for the long-term viability of UK-based sites.

This symposium will review advances in laboratory efficiency which, both individually and collectively, are designed to achieve these outcomes, through the adoption of process-based improvement tools, automation and integrated data handling within the laboratory.

abstract: This workshop will present drug release methodologies to evaluate the product performance for special dosage forms, such as, buccal, topical, ophthalmic, inhalation, stent and nanoparticle formulations. It will provide opportunities for the participants to interact with the faculty in panel discussions.

abstract: Bio-International 2008 aims to develop a common approach for tackling complex issues such as Bioequivalence/interchangeability of Cytotoxic Drug Products, Topical Drug Products and Respiratory Drug Products. The use of Comparator Drug Products for establishing Bioequivalence is a burning issue in the assessment of Multisource Drug Products quality and will be discussed along with application of Biopharmaceutics Classification System in assessing Bioequivalence of oral products. There will also be a special session highlighting BE issues in many countries and how these issues can be resolved with the experience gained with similar issues in other parts of the world. The format of Bio-International 2008 will include plenary presentations by leading international experts, panel discussions and questions from delegates for response by speakers.

The conference is designed to follow the pre-satellite FIP/SIG workshop Special dosage forms – What’s new with in vitro drug release? (20-21 October, RPSGB, London). Delegates at this conference are invited to sign-up for both events for a discounted combined fee.

For further details on the workshop, please see www.rpsgb.org/worldofpharmacy/events or email science@rpsgb.org.

abstract: This 2 day course considers the regulatory aspects of the fine chemical and pharmaceutical industries, with emphasis on their practical application in chemical development. Its purpose is to encourage chemists based in lab or pilot plant to develop a balanced and practical perspective on GMP.

abstract: While the UK pharmacy degree continues to be internationally recognised for its scope and quality, it is nevertheless essential to ensure that there is a suitable level of connection between the educational outputs of the degree and the needs of the profession. This meeting is intended to bring together academics, policy makers, employers and recent graduates in order to exchange views on how we should address current needs and future changes in the profession at the undergraduate level.

abstract: An intensive course on the formulation, production and properties of pharmaceutical tablets. This course will examine the basic concepts of equipment selection, granulation and end-point determination, formulation optimisation and prediction, in-process monitoring (PAT), film coating and official and non-official dissolution tests. The course is designed to be applicable to the day to day problems of tabletting, linked to a sound theoretical knowledge of the principles involved.

abstract: All cells contain a diverse range of repair pathways that have evolved to optimize their survival following damage to their DNA. These pathways involve the actions of a large number of DNA repair proteins to remove the damage and maintain genome stability. Clearly, when these processes do not function correctly, a likely result will be instability of the genome. A large body of experimental data has demonstrated that such genetic instability can cause a wide variety of human diseases. This meeting will highlight recent major advances in understanding biochemical details about how DNA repair intersects with cellular pathways that lead to cancer or ageing. The meeting is particularly timely since it is now apparent that these biochemical processes offer significant potential for novel therapies to treat diseases such as cancer.